Website
N/ATelephone
N/A
Address
Description
BCAL Diagnostics Ltd. develops screening tests for the early detection of breast cancer. It also associated lipids, biomarker blood test that is used for prevention, screening and monitoring. The company was founded by Jayne Shaw and Ron Philips in 2010 and is headquartered in Sydney, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.05 - 0.21
Trade Value (12mth)
AU$4,519.00
1 week
0%
1 month
-4.76%
YTD
53.85%
1 year
42.86%
All time high
0.275
EPS 3 yr Growth
650.000%
EBITDA Margin
N/A
Operating Cashflow
-$6m
Free Cash Flow Return
-76.80%
ROIC
-64.30%
Interest Coverage
-485.40
Quick Ratio
2.70
Shares on Issue (Fully Dilluted)
212m
HALO Sector
Healthcare
Next Company Report Date
27-Aug-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
31 October 23 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
31 October 22 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
31 January 22 |
Becoming a substantial holder
×
Becoming a substantial holder |
30 June 23 |
Proposed issue of securities - BDX
×
Proposed issue of securities - BDX |
30 June 23 |
Notification regarding unquoted securities - BDX
×
Notification regarding unquoted securities - BDX |
30 August 23 |
Share Purchase Plan Offer Booklet
×
Share Purchase Plan Offer Booklet |
30 August 23 |
Preliminary Final Report
×
Preliminary Final Report |
30 August 22 |
Preliminary Final Report
×
Preliminary Final Report |
29 September 23 |
Appendix 4G & Corporate Governance Statement
×
Appendix 4G & Corporate Governance Statement |
29 September 23 |
Annual Report to shareholders
×
Annual Report to shareholders |
29 September 22 |
Annual Report to shareholders
×
Annual Report to shareholders |
29 September 22 |
Appendix 4G and Corporate Governance Statement
×
Appendix 4G and Corporate Governance Statement |
29 November 23 |
Collaboration with KIMS & Indo-American Hospitals Hyderabad
×
Collaboration with KIMS & Indo-American Hospitals Hyderabad |
29 November 22 |
BCAL AGM Presentation
×
BCAL AGM Presentation |
29 November 22 |
Results of Meeting
×
Results of Meeting |
29 December 21 |
Application for quotation of securities - BDX
×
Application for quotation of securities - BDX |
29 August 23 |
Proposed issue of securities - BDX
×
Proposed issue of securities - BDX |
29 August 22 |
Application for quotation of securities - BDX
×
Application for quotation of securities - BDX |
28 September 21 |
Annual Report to shareholders
×
Annual Report to shareholders |
28 October 22 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
28 October 22 |
Letter to Shareholders on Annual General Meeting Notice
×
Letter to Shareholders on Annual General Meeting Notice |
28 November 23 |
Change in substantial holding
×
Change in substantial holding |
28 November 23 |
Director Change of Interest Notices X 4
×
Director Change of Interest Notices X 4 |
28 June 22 |
BCAL Enters US Product Development Agreement with Precion
×
BCAL Enters US Product Development Agreement with Precion |
28 July 23 |
Shares and Options Released from Escrow
×
Shares and Options Released from Escrow |
28 July 23 |
Application for quotation of securities - BDX
×
Application for quotation of securities - BDX |
28 July 22 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
28 August 23 |
$2.4m Capital Raise to Further BREASTEST Commercialisation
×
$2.4m Capital Raise to Further BREASTEST Commercialisation |
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.